BofA Securities Reiterates Buy Rating on Insmed (INSM); 'pullback overdone'

May 12, 2026 12:02 PM

BofA Securities analyst Jason Zemansky reiterated a Buy rating and $214.00 price target on Insmed (NASDAQ: INSM) saying the Brinsupri ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found